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The snake neurotoxin a-bungarotoxin (a-Bgtx) is a competitive antagonist at nicotinic acetylcholine
receptors (nAChRs) and is widely used to study their function and cell-surface expression. Increasingly,
a-Bgtx is also used as an imaging tool for ﬂuorophore-labelling studies, and given the structural con-
servation within the pentameric ligand-gated ion channel family, we assessed whether a-Bgtx could bind
to recombinant and native g-aminobutyric type-A receptors (GABAARs). Applying ﬂuorophore-linked a-
Bgtx to recombinant axb1/2g2 GABAARs expressed in HEK-293 cells enabled clear cell-surface labelling
of a2b1/2g2 contrasting with the weaker staining of a1/4b1/2g2, and no labelling for a3/5/6b1/2g2. The
labelling of a2b2g2 was abolished by bicuculline, a competitive antagonist at GABAARs, and by d-
tubocurarine (d-Tc), which acts in a similar manner at nAChRs and GABAARs. Labelling by a-Bgtx was also
reduced by GABA, suggesting that the GABA binding site at the receptor bea subunit interface forms part
of the a-Bgtx binding site. Using whole-cell recording, high concentrations of a-Bgtx (20 mM) inhibited
GABA-activated currents at all axb2g2 receptors examined, but at lower concentrations (5 mM), a-Bgtx
was selective for a2b2g2. Using a-Bgtx, at low concentrations, permitted the selective inhibition of a2
subunit-containing GABAARs in hippocampal dentate gyrus granule cells, reducing synaptic current
amplitudes without affecting the GABA-mediated tonic current. In conclusion, a-Bgtx can act as an in-
hibitor at recombinant and native GABAARs and may be used as a selective tool to inhibit phasic but not
tonic currents in the hippocampus.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The snake venom neurotoxin, a-bungarotoxin (a-Bgtx), binds as
an inhibitor with high afﬁnity to nicotinic acetylcholine receptors
(nAChRs), including the heteromeric muscle receptors composed of
abgd or abdε subunits, and homomeric neuronal subtypes,
comprising a7, a8, or a9 subunits (Olsen and Sieghart, 2008; Pirker
et al., 2000; Whiting et al., 1995). The g-aminobutyric acid (GABA)
type-A receptors (GABAARs) are Cl permeable ligand-gated ion
channels from the same pentameric Cys-loop superfamily of re-
ceptors as nACh, 5-HT3 and glycine receptors (Smart and Paoletti,
2012). Members of this family share a common structuralg-aminobutyric type-A re-
tylcholine receptors; a-Bgtx-
A, paraformaldehyde; IPSCs,
, dentate gyrus granule cells.
r Ltd. This is an open access articlarchitecture, including an N-terminal extracellular ligand-binding
domain and four a-helical transmembrane-spanning domains
(Corringer et al., 2012; Miller and Smart, 2010; Thompson et al.,
2010). It has long been of interest that two antagonists at
nAChRs, d-tubocurarine (d-Tc; Caputi et al., 2003; Simmonds, 1982;
Wotring and Yoon, 1995) and trimethapan (Wotring and Yoon,
1995) are also inhibitors at GABAARs. In addition, a-Bgtx can also
inhibit homomeric b3 subunit-containing GABAARs by binding at
the subunit interfaces (McCann et al., 2006). Whilst it is unclear
whether b3 homomers constitute a deﬁned physiological popula-
tion of GABAARs, if a-Bgtx can bind at the b3eb3 subunit interface,
it is plausible that more physiological ab subunit-containing
GABAARs (Brickley et al., 1999; Mortensen and Smart, 2006;
Sieghart and Sperk, 2002) may be susceptible to block by a-Bgtx
by virtue of their beb subunit interface. By contrast, such an
interface should be absent in the more prevalent synaptic-type abg
GABAARs (Smart and Paoletti, 2012). We therefore investigated
whether non-b3 subunit-containing physiologically-relevant
GABAAR subtypes can bind a-Bgtx and if so, what are the functional
consequences.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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we reveal that from a selection of axb2g2 heteromers, a-Bgtx
inhibited a2b2g2 receptors to the greatest extent. Furthermore,
ﬂuorescent a-Bgtx coupled to Alexa-Fluor 555 (a-Bgtx-AF555)
yielded robust staining of a2b2g2 receptors. This was abolished by
d-Tc and by the competitive antagonist at GABAARs, bicuculline, as
well as by GABA, suggesting that the a-Bgtx-binding site on the
GABAAR heteromers is most probably located at the bea interface.
We also found that a-Bgtx inhibited GABA currents in hippocampal
neurons, reducing the amplitudes of synaptic currents. Overall, a-
Bgtx is an inhibitor at GABAARs displaying some selectivity for the
a2 subunit-containing isoform.
2. Methods
2.1. cDNA, plasmids, and drugs
Murine GABAAR a1-6, b1-3, g2 and d cDNAs subcloned into pRK-5 and pEGFP-C1
have been described previously (Mortensen et al., 2011).
2.2. Cell culture and transfection
HEK-293 cells were maintained at 37 C in a humidiﬁed 95% air/5% CO2 atmo-
sphere in Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with 10% (v/
v) fetal calf serum (FCS), penicillin-G and streptomycin (100 units/ml and 100 mg/
ml), 2 mM L-glutamine. Cells were plated onto 22mmglass coverslips (VWR), coated
with poly-L-lysine (Sigma). All media components were from Life Technologies
unless otherwise stated.
Cells were transfected with equimolar ratios of cDNAs encoding for a1e6, b1e3
and d or g2 GABAA receptor subunits along with eGFP using a calcium phosphate
method (Mortensen et al., 2011) 15e45 min after plating.
2.3. Primary hippocampal cultures
Dissociated hippocampal neurons were prepared from embryonic day 18 rat
pups as described (Hannan et al., 2012). Brieﬂy, hippocampi were dissected in ice-
cold Hank's Balanced Salt Solution (HBSS) (Ca2þ/Mg2þ free) before enzymatic
dissociation in 0.1% (w/v) trypsin at 37 C for 10 min followed by serial washes in
pre-warmed HBSS to remove trypsin prior to trituration. Cells were mechanically
dissociated using ﬁre-polished glass Pasteur pipettes in plating medium composed
of minimal essential medium (MEM) supplemented with 5% (v/v) fetal calf serum
(FCS), 5% (v/v) horse serum, penicillin-G and streptomycin (200 units/ml and 200 mg/
ml), 2 mM L-glutamine and 35 mM glucose. Cells were plated at a density of 106 per
ml in plating medium on glass cover-slips previously coated with poly-D-lysine. The
neurons were grown and maintained at 37 C in a humidiﬁed 95% air/5% CO2
atmosphere.
After plating (30 min), the medium was removed and replaced with mainte-
nance medium composed of Neurobasal-A supplemented with 1% (v/v) B-27,
penicillin-G and streptomycin (100 units/ml and 100 mg/ml), 0.5% (v/v) Glutamax
and 35 mM glucose.
2.4. Preparation of brain slices
Acute transverse brain slices were prepared from adult (P115e125) male C57BL/
6J mice in accordance with the UK Animals (Scientiﬁc Procedures) Act 1986.
The brain was rapidly removed after terminal anaesthesia with isoﬂurane and
immersed in ice-cold slicing solution composed of (mM): 85 NaCl, 2.5 KCl, 1 CaCl2, 4
MgCl2, 1.25 NaH2PO4, 26 NaHCO3, 75 sucrose, and 25 glucose, 2 kynurenic acid, pHe
7.4. The slicing solution was continuously bubbled with 95% air and 5% CO2.
Transverse 250 mm slices containing the ventral hippocampus were cut with a Leica
VT1200S vibroslicer. The slicing solution was exchanged at 37 C for 60 min with a
recording solution containing (mM): 125 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 1.25
NaH2PO4, 26 NaHCO3, 2 kynurenic acid, and 25 glucose, pH 7.4.
2.5. Whole-cell patch-clamp electrophysiology
Whole-cell GABA-activated currents were recorded from transfected HEK-293
cells or hippocampal neurons in culture at 12e14 DIV using patch clamp electro-
physiology. Patch electrodes had resistances of 4e5 MU and were ﬁlled with an
internal solution containing (mM): 120 CsCl 1 MgCl2, 11 EGTA, 30 KOH, 10 HEPES, 1
CaCl2, and 2 K2ATP; pH e 7.2. HEK-293 cells were superfused with a saline solution
containing (mM): 140 NaCl, 4.7 KCl, 1.2 MgCl2, 2.52 CaCl2, 11 Glucose, and 5 HEPES;
pH 7.4. The saline for recording from primary neurons was supplemented with
2 mM kynurenic acid and pH adjusted to 7.4 to block all spontaneous excitatory
post-synaptic currents (EPSCs). Membrane currents were ﬁltered at 5 kHz (3 dB,
6th pole Bessel, 36 dB/octave). HEK-293 cells were studied 48 h after transfection by
voltage clamping cells at a holding potential of20 to40mVwith optimised series
resistance (Rs, <10 MU) and whole-cell membrane capacitance compensation.
Neuronal membrane currents were similarly recorded at a holding potentialof 60 mV. Changes of Rs greater than 10% during the experiment resulted in the
recording being excluded from analysis.
GABA concentrationeresponse curves were generated bymeasuring the current
(I) at each GABA concentration, applied at suitable time intervals, and normalizing
the current to the maximum GABA response (Imax), before ﬁtting the concentration
response relationship with:
I

Imax ¼
ð1=1Þ þ ðEC50=AÞn

where A is the concentration of GABA, EC50 is the concentration of GABA giving 50%
of the maximum response and n is the Hill slope.
For studying inhibition, a-Bgtx was either co-applied, or pre-applied for
30e60 s, followed by co-applicationwith sub-maximal doses of GABA. Spontaneous
inhibitory postsynaptic currents (IPSCs) were recorded from dentate gyrus granule
cells (DGGCs) with the same internal solution as above. Cells were voltage clamped
at 60 mV and IPSCs were recorded using 5 kHz ﬁltering with optimal series
resistance and whole-cell capacitance compensation.
IPSCs were detected and analysed using WinEDR and WinWCP (John Dempster,
University of Strathclyde, UK). IPSC frequency was calculated using events detected
over 60 s epochs of recording. For IPSC amplitudes, in excess of several thousand
IPSCs were recorded and analysed as overall mean and then displayed as an
amplitude distribution and ﬁtted with a sum of 1e4 Gaussian functions of the form:
f ðxÞ ¼ A e
ðxmÞ2=2si2
s
ﬃﬃﬃﬃﬃﬃ
2p
p þ C
Where A deﬁnes the amplitude and C is a constant deﬁning the pedestal of the
histogram. This function provided the Gaussian mean amplitude current (m) and
standard deviation (s). All the distributions were ﬁtted using this function in Origin
(Ver 6). The accuracy of the ﬁts was checked by repeating the iterative non-linear
ﬁtting procedure after substituting the best-ﬁt parameters obtained for the con-
trol and a-Bgtx datasets with new values.
For tonic inhibition, to determine the average holding currents, a 60 s contin-
uous current recording was sampled every 1 s, discarding epochs that coincided
with IPSCs. Any effect of drugs on the holding current was deﬁned by subtracting the
average holding currents in control and during drug application.
The baseline noise (RMS) was calculated before and during drug treatment. This
was estimated from a continuous (30 s) current recording, sampled every 100 ms.
The median current was calculated every 5 s and values more than twice the
standard deviation from themedian (usually due to IPSCs) were eliminated. Baseline
GABA-mediated current noise was deﬁned by subtracting RMS values before and
after drugs, e.g., a-Bgtx or bicuculline.
2.6. Fluorescent a-Bgtx staining and imaging
Live transfected HEK-293 cells were studied 48 h after transfection and washed
with Krebs to remove cell culture media and incubated in 400 nM a-Bgtx coupled
with Alexa Fluor 555 (a-Bgtx-AF555; Life Technologies) for 10 min at room tem-
perature (RT). Cells were washed and ﬁxed in 4% paraformaldehyde (PFA; Sigma) for
10 min at RT. The cells were imaged immediately post-ﬁxation in saline using a Zeiss
LSM 510 Meta confocal microscope and an Achroplan x40 water DIC objective (NA
0.8) as described previously (Hannan et al., 2012). This involved choosing the
optimal z-section and acquiring images as a mean of 4 scans in 16-bits using a
543 nm HeliumeNeon laser and a 560 nm long-pass ﬁlter for a-Bgtx-AF555 and a
488 Argon laser with a 505e530 nm band-pass ﬁlter for eGFP.
In experiments using permeabilisation, cells were ﬁxed in 4% PFA for 10 min at
RT followed by washes (x3) in phosphate buffered saline (PBS; Sigma) and 0.1%
triton-X100 (Sigma) was added for 10 min at RT in 10% (v/v) FCS. Cells were washed
to remove the detergent and 400 nM a-Bgtx-AF555 was added for 10 min at RT to
label intracellular receptors.
2.7. Image analysis
Confocal images were analysed using ImageJ (version 1.410) as described pre-
viously (Hannan et al., 2013). For each cell the surface membrane was identiﬁed by
drawing a region-of-interest (ROI) in the eGFP channel and this was transferred to
the a-Bgtx-AF555 channel and the mean membrane ﬂuorescence values were
determined. Mean background ﬂuorescence was determined from a region devoid
of cells. This was subtracted from the mean membrane ﬂuorescence providing a
mean corrected ﬂuorescence intensity value. These values, for different combina-
tions of receptors and drugs, were graphically plotted using Origin.
3. Results
3.1. Bungarotoxin inhibits GABAA receptors in hippocampal neurons
Heteromeric abg receptors are a predominant GABAAR subtype
in the neocortex, including the hippocampus (Olsen and Sieghart,
2008; Pirker et al., 2000; Whiting et al., 1995). A smaller
S. Hannan et al. / Neuropharmacology 93 (2015) 28e4030proportion of receptors in these areas are thought to be ab het-
eromers, but to date, there is little if any direct evidence to support
the existence of b3 homomers in neurons (Mortensen and Smart,
2006). Before commencing recombinant receptor studies, we ﬁrst
examined a-Bgtx and two other nAChR antagonists for their ability
to inhibit whole-cell GABA-activated currents in primary hippo-
campal neurons, which express heteromeric GABAARs.
Receptors were activated by GABA (EC50 ¼ 1.23 ± 0.04 mM;
n ¼ 10; Fig. 1A) in the presence of 2 mM kynurenic acid to block
excitatory postsynaptic currents (EPSCs). The potent a7 nAChR
speciﬁc antagonist methyllaconitine (MLA) did not affect currents
activated by sub-maximal GABA (10 mM) concentrations, either
when co-applied with GABA (<1% of control; data not shown) or
when co-applied with GABA after a 1min pre-incubationwith 1 nM
MLA (0.8 ± 1.7% inhibition; n ¼ 6; P > 0.05; Fig. 1BeC) indicating
that MLA is not an antagonist at GABAARs.
The non-selective nAChR antagonist, d-tubocurarine (d-Tc), is a
known competitive antagonist at GABAARs (Simmonds,1986) in theFig. 1. Inhibition of native hippocampal GABAARs by d-Tc and a-Bgtx. A, GABA concentr
currents recorded from rat hippocampal neurons in culture (12e14 DIV) in response to 10 mM
(D,E); þ5 mM a-Bgtx and 1 nM MLA (F,G). Example control traces also show the potentiation
for 1 min before co-application with GABA. Bargraph data presented here and in succeeding
ANOVA.cuneate nucleus (Simmonds, 1982), substantia nigra (Caputi et al.,
2003), and hippocampus (Lebeda et al., 1982; Wotring and Yoon,
1995). As expected, 100 mM d-Tc substantially inhibited whole-
cell GABA-activated currents in cultured hippocampal neurons
(92 ± 4% inhibition; n ¼ 5; P < 0.001, Fig. 1DeE).
We next introduced a-Bgtx, a non-selective competitive nAChR
antagonist. Pre-applying 5 mM a-Bgtx to cultured hippocampal
neurons for 1 min in the presence of 1 nM MLA (to inhibit any
crosstalk with endogenous nAChRs) followed by co-applicationwith
10 mM GABA resulted in signiﬁcant inhibition of GABA currents (by
33±9%;n¼8;P<0.01; Fig.1FeG). Theeffectofa-Bgtxwas reversible
with GABA currents returning to control levels after 60 s recovery
(Fig. 1G; P < 0.05). As a control, these receptors were alsomodulated
by pentobarbital with 1 mM GABA currents being potentiated by
20 mM pentobarbital in the same neurons (Fig. 1B, D, F).
These data indicated that a-Bgtx can antagonise GABA-activated
currents in neurons, but the level of inhibition was surprisingly
high given that we would expect only a very small proportion, ifation response curve from primary hippocampal neurons. Whole-cell GABA-activated
GABA (left hand panels) and GABA þ 1 nM MLA (B,C); þ100 mM d-tubocurarine (d-Tc)
of 1 mM GABA currents with 20 mM pentobarbital. MLA and or a-Bgtx were pre-applied
ﬁgures are means ± S.E.M, n ¼ 5e8 cells; *P < 0.05, **P < 0.01, ***P < 0.001; One-way
S. Hannan et al. / Neuropharmacology 93 (2015) 28e40 31any, of native GABAARs to contain a b3eb3 interface. These results
therefore suggested that a-Bgtx may be an antagonist at native
heteromeric GABAARs, and possibly target a binding site that is
discrete from the beb subunit interface.3.2. Bungarotoxin binds to a subset of recombinant GABAAR
heteromers
Having established that a-Bgtx is an antagonist at native
GABAARs, we explored its ability to bind to recombinant GABAAR
subtypes considered to be physiologically relevant. To avoid any
confounds, we did not include b3 subunits because of the potential
to form b3eb3 interfaces which would bind a-Bgtx as previously
reported (McCann et al., 2006).
We ﬁrst investigated the binding of a-Bgtx coupled to Alexa-
Fluor 555 (a-Bgtx-AF555) to cell surface receptors expressed inFig. 2. GABAAR heteromers bind to Alexa Fluor 555-labelled a-Bgtx. HEK-293 cells expres
a-Bgtx coupled to Alexa Fluor 555 (a-BgTx-AF555), 48 h post-transfection, for 10 min at RT.
surface ﬂuorescence of a-Bgtx-AF555 bound to GABAARs expressing eGFP alone, or eGFP an
traces of whole-cell 10 mM GABA-activated currents recorded from HEK cells expressing a3HEK-293 cells composed of an a subunit (a1-a6) with either b1g2
(Fig. 2AeB) or b2g2 (Fig. 2CeD) subunits. Of these combinations, a2
subunit-containing receptors demonstrated the highest cell surface
staining with a-BgTx-AF555 (Fig. 2A, C). The mean cell surface
ﬂuorescence of cells expressing a2b1g2 (ﬂuorescence
intensity ¼ 1057 ± 64 a.u., n ¼ 6; Fig. 2AeB) and a2b2g2 (ﬂuo-
rescence intensity ¼ 1294 a.u., n ¼ 6; Fig. 2CeD) were signiﬁcantly
higher compared to cells expressing only eGFP (ﬂuorescence
intensity ¼ 9 ± 4 a.u., n ¼ 6; P < 0.001; one way ANOVA; Fig. 2B, D).
Weaker staining intensities were measured for a-Bgtx-AF555
binding to other receptor isoforms: a1b1g2 (592 ± 46 a.u., n ¼ 6;
Fig. 2AeB), a1b2g2 (324 ± 33 a.u., n ¼ 6; Fig. 2CeD), a4b1g2
(90 ± 64 a.u., n ¼ 6; Fig. 2A, C), and a4b2g2 (64 ± 56 a.u., n ¼ 6;
Fig. 2B, D). These staining intensities for a1b1/2g2, but not for a4b1/
2g2, were signiﬁcantly greater compared to eGFP alone (P < 0.001).
Receptors containing a3/5/6 subunits and b1/2g2 did not show anysing eGFP, a1-6 and g2 with either b1 (A) or b2 (C) subunits, were incubated in 400 nM
Cells were washed to remove excess a-Bgtx-AF555, ﬁxed and imaged. (B,D) Mean cell
d a1-6b1g2 (B) or a1-6b2g2 (D). ***P < 0.001, n ¼ 6e9 cells; Scale bar 5 mm. Example
/5/6b2g2 demonstrate the functional expression of these receptors.
S. Hannan et al. / Neuropharmacology 93 (2015) 28e4032labelling with a-BgTx-AF555 (P > 0.05). The imaging data
demonstrated that a-Bgtx binds to several combinations of physi-
ologically important heteromeric GABAARs in HEK-293 cells and
that binding does not require the presence of one or more b3
subunits.
To discount the possibility that the failure of a-Bgtx to bind to
receptors containing a3/5/6 subunits was due to poor receptor
expression, we used patch clamp recording to examine their
responsiveness to GABA. Expressing a3/5/6 subunits with b2g2
subunits produced receptors that supported robust GABA currents
(Fig 2E) conﬁrming that the lack of staining observed with a-Bgtx
for these receptors was not due to a lack of expression.
3.3. Bungarotoxin selectively inhibits a2 subunit-containing
receptors
To complement our imaging studies we next examined the ef-
fect of a-Bgtx on GABAAR function using whole-cell patch electro-
physiology in HEK-293 cells expressing axb2g2 receptor subtypes.
We selected the following subunit combinations based on their
relative abundance in the hippocampal stratum pyramidale: a1b2g2
and a2b2g2, reﬂecting their relative importance as non-b3-Fig. 3. a-Bgtx inhibition at GABAARs expressed in HEK293 cells. A, GABA concentration res
cells. B, GABA current proﬁles for a4b2g2 receptors in response to 3 mM GABA, and þ20 m
proﬁles. C, Representative whole-cell GABA-activated currents in response to submaximal co
(pre-applied for 1 min) for cells expressing a1b2g2, a2b2g2, a4b2g2 and a5b2g2 receptor
(a1b2g2), and 3 mM (a2b2g2, a4b2g2, and a5b2g2). Lines are drawn (n ¼ 3). E, Inhibition at
was statistically signiﬁcant compared to a1b2g2 (**P < 0.01), and a4b2g2 and a5b2g2 (*P <
currents in response to maximal concentration of GABA (1 mM) in the presence of 5 mM acontaining synaptic GABAARs; a4b2g2 and a5b2g2, chosen since
they may represent forms of extrasynaptic GABAARs in the hippo-
campus that underpin tonic inhibition (Glykys et al., 2008).
The ability of 1, 5 or 20 mM a-Bgtx to inhibit submaximal GABA
currents was examined. The GABA concentrations used were 6 mM
for a1b2g2, and 3 mM for a2b2g2, a4b2g2, and a5b2g2, based on
their pre-determined GABA EC50s of: 6.6 mM (a1b2g2; pEC50
5.18 ± 0.06, n ¼ 34); 2.76 mM (a2b2g2; pEC50 5.46 ± 0.09, n ¼ 5);
1.68 mM (a4b2g2; pEC50 5.78 ± 0.05, n ¼ 5); and 2.44 mM (a5b2g2;
pEC50 5.61 ± 0.24, n ¼ 5; Fig. 3A).
For these receptor subtypes there were notable differences in
the GABA current proﬁles as expected from their subunit compo-
sition (Mortensen et al., 2011; Picton and Fisher, 2007). Differences
in GABA current proﬁles were also observed depending onwhether
a-Bgtx was co-applied with GABA or also pre-applied for 1 min
(Fig. 3B). The level of block was increased by pre-application of a-
Bgtx and the slow sag in the GABA current, evident from just co-
applying a-Bgtx, suggested that the toxin binds to GABAARs with
a slow on-binding rate. Therefore, to achieve a full steady-state
block, a-Bgtx was pre-applied.
Using this protocol, GABA currents at all GABAAR subtypes
examined were inhibited by the highest concentration of a-Bgtxponse curves for a1b2g2, a2b2g2, a4b2g2, and a5b2g2 receptors expressed in HEK-293
M a-Bgtx (with or without pre-application for 1 min). Inserts show expanded current
ncentrations of GABA in the absence (left-panels) or presence of 1, 5 and 20 mM a-Bgtx
s. D, Inhibition of GABA-activated currents by a-Bgtx. GABA concentrations are 6 mM
receptors by 1 and 5 mM a-Bgtx. With 5 mM a-Bgtx, the inhibition observed at a2b2g2
0.05) receptors, n ¼ 3, One-way ANOVA. F, Representative whole-cell GABA-activated
-Bgtx and after recovery from inhibition.
S. Hannan et al. / Neuropharmacology 93 (2015) 28e40 33tested (20 mM), with currents mediated by a2b2g2 showing the
most inhibition, and a5b2g2 the least. The level of inhibition at
20 mM a-Bgtx in ascending order (Fig. 3CeD) is: 15.3 ± 5.9%
(a5b2g2), 23.8 ± 3% (a1b2g2), 41.3 ± 4.4% (a4b2g2), and 62.3 ± 5%
(a2b2g2) (n ¼ 3).
At lower concentrations of a-BgTx (5 mM) however, inhibition
was only observed at a2b2g2 receptors (Fig. 3CeE). These results
are consistent with our data from ﬂuorescent a-BgTx labelling with
a2b2g2 and correlates the highest levels of staining with a low
concentration (400 nM) of a-BgTx-AF555 (Fig. 2) with the highest
sensitivity to block by a-Bgtx (Fig. 3DeE).
To examine the nature of a-Bgtx inhibition at GABAARs, we
applied 5 mM a-BgTx with 1 mM GABA, to study antagonism at
saturating GABA concentrations. Saturating GABA currents wereFig. 4. a-Bgtx binds at the bea subunit interface of GABAARs. A, Schematic of the experi
were incubated in drug for 5 min at RT followed by the addition of drug þ400 nM a-Bgtx-AF5
excess a-Bgtx-AF555, ﬁxed and imaged. B, Images of cells expressing a2b2g2, stained with a
cell surface ﬂuorescence of a-Bgtx-AF555 bound to surface GABAARs in the presence of d-Tc,
in the presence of 250 mM GABA, 50 mM bicuculline, 1 mM d-Tc, 500 nM ﬂunitrazepam or 20
the presence of: GABA, bicuculline, d-Tc, ﬂunitrazepam, picrotoxin. F, 5 mM GABA-activated c
a2b2g2 or a2b2 receptors, 48 h post-transfection. ***P < 0.001, **P < 0.01; n ¼ 6e7. Scalereduced by 13.0 ± 5.9% (n ¼ 3) in the presence of a-BgTx indicative
of some mixed-non competitive antagonism (Fig. 3F).
3.4. b-a subunit interface forms a bungarotoxin-binding site in
GABAARs
To identify the location of the a-Bgtx binding site on GABAARs,
we pre-incubated HEK-293 cells expressing a2b2g2 with a range of
ligands that act at GABAARs and nAChRs, for 5min at RT followed by
co-incubation with a-Bgtx-AF555 for 10 min at RT (Fig. 4A). These
ligands were selected to ‘protect by binding occupancy’ known
binding site domains on GABAARs and nAChRs.
We ﬁrst studied the effect of some well-characterised nAChR
ligands on a-Bgtx-AF555 binding to a2b2g2 GABAARs on themental protocol. 48 hrs after transfection, HEK-293 cells expressing eGFP and a2b2g2
55 for 10 min at RT to label cell surface receptors. The cells were washed to remove the
-Bgtx-AF555 in the presence of 1 mM d-Tc, 1 mM nicotine, or 1 mM carbachol. C, Mean
nicotine or carbachol. D, Images of cells expressing a2b2g2, stained with a-Bgtx-AF555
mM picrotoxin. E, Mean cell surface ﬂuorescence of a-Bgtx-AF555 bound to GABAARs in
urrents and mean (±sem) inhibition caused by 5 mM Zn2þ for HEK-293 cells expressing
bars 5 mm.
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receptor types. Neither of the nAChR agonists, 1 mM nicotine
(90.5 ± 11.4% of control, P > 0.05, one-way ANOVA) nor 1 mM
carbachol (100.5 ± 11.3% of control, P > 0.05), had any effect on the
binding of a-Bgtx-AF555 to a2b2g2 (n¼ 7, Fig. 4BeC); however, the
antagonist, d-Tc (1mM) abolished a-Bgtx-AF555 binding (1.8± 1.3%
of control, n ¼ 7; Fig. 4BeC; P < 0.001).
As d-Tc is a competitive antagonist at GABAARs (Wotring and
Yoon, 1995), the abolition of a-Bgtx-AF555 staining suggested
that the GABA-binding bea interface may form the a-Bgtx-binding
site on a2b2g2 heteromers. In HEK-293 cells, transfected a2, b2,
and g2 subunits are thought to assemblewith a subunit order of b2-
a2-b2-a2-g2, and therefore, b2-b2 interfaces should be absent
(Smart and Paoletti, 2012).
We next studied the effects of selective ligands for GABAARs on
a-Bgtx-AF555 binding to a2b2g2. The benzodiazepine (BDZ) ﬂu-
nitrazepam (500 nM), which potentiates GABAAR currents by
binding at the a-g interface (Pritchett et al., 1989; Richter et al.,
2012; Sigel, 2002) did not affect a-Bgtx-AF555 binding to a2b2g2
(105. 5 ± 16.5% of control, n ¼ 6; Fig. 4DeE; P > 0.05, One-way
ANOVA). The non-competitive GABA channel blocker, picrotoxin
(20 mM), also had no effect on a-Bgtx-AF555 binding (106.7 ± 14.9%Fig. 5. a-Bgtx-AF555 binds to b3 but not b1 or b2 subunits. A, Images of HEK-293 cells ex
for 10 min at RT, 48 h after transfection, washed to remove the excess a-Bgtx-AF555, ﬁxed a
subunits. ***P < 0.001, n ¼ 6e9. C, Images of HEK-293 cells expressing eGFP with or with
permeabilised with 0.1% w/v Triton-X100, and incubated in 400 nM a-Bgtx-AF555 for 10 mi
a-Bgtx-AF555. Scale bars 5 mm (A) and 10 mm (C).of control, n ¼ 6; Fig. 4DeE; P > 0.05). These results indicated that
the a-g interface and deep within the ion channel pore are unlikely
sites for a-Bgtx binding to GABAARs.
We then explored the bea interfaces which form the GABA
binding sites in GABAARs (Sieghart, 1995). GABA (250 mM) reduced
a-Bgtx-AF555 binding signiﬁcantly (34.9 ± 7.1% of control, n ¼ 6;
Fig. 4DeE; P < 0.001); and the competitive antagonists, bicuculline
(50 mM) (7. 5 ± 1.5% of control, n¼ 6; Fig. 4DeE; P < 0.001) and d-Tc
(1 mM) (7.1 ± 1.9% of control, n ¼ 6; Fig. 4DeE; P < 0.001), virtually
eliminated a- Bgtx-AF555 binding to a2b2g2, supporting a role for
the bea interface in binding a-Bgtx to GABAARs.
To ascertain whether our abg receptors were assembled intact
ensuring the absence of beb subunit interfaces, we studied the
inhibition caused by Zn2þ at a2b2g2 receptors. Receptors
composed of ab subunits will be inhibited signiﬁcantly more by
Zn2þ when compared to abg receptors (Hosie et al., 2003; Krishek
et al., 1998). Consistent with this, we found that 10 mM Zn2þ
signiﬁcantly inhibited submaximal (5 mM) GABA currents for a2b2
by 90.8 ± 4.44% (n ¼ 3; Fig. 4F; P < 0.01) compared to 37.4 ± 8.9 for
a2b2g2 (n ¼ 3) suggesting that most of the receptors used in the
imaging studies are likely to contain g2 subunits. Furthermore,
given that our results so far suggest that a-Bgtx binds to the beapressing eGFP with either b1, b2 or b3 subunits, incubated with 400 nM a-Bgtx-AF555
nd imaged. B, Mean surface membrane ﬂuorescence of cells expressing eGFP and b1e3
out either b1, b2 or b3 subunits, after ﬁxation in 4% PFA, 48 h after transfection, and
n at RT, washed and imaged. Arrowheads indicate intracellular structures labelled with
S. Hannan et al. / Neuropharmacology 93 (2015) 28e40 35interface, the incorporation of the g2 subunit is unlikely to be the
determining factor for a-Bgtx binding to GABAARs.
Given that the b3eb3 interface forms an a-Bgtx binding site, and
that GABA receptor b subunits are highly homologous, we investi-
gated whether the b1eb1 or b2-b2 interfaces could also form a-
Bgtx binding sites. However, for cells expressing b1, b2 or b3
homomers in HEK-293 cells for 48 h and incubated in a-Bgtx-
AF555 with or without permeabilisation, only b3 expressing cells
showed high levels of cell surface and intracellular staining with a-
Bgtx-AF555 (Fig. 5AeC). Such staining was absent for b1 and b2
subunits discounting the possibility that beb subunit interfaces
were the sites for a-Bgtx binding in b1 or b2 subunit-containing
heteromeric GABAARs.
3.5. Bungarotoxin inhibits only phasic GABA currents in dentate
gyrus granule cells
Having established the selectivity of micromolar a-Bgtx con-
centrations for inhibiting a2b2g2 receptors, we assessed the
sensitivity of native GABAARs in adult (P115e125) mouse acute
hippocampal slices to nAChR ligands and to a-Bgtx. Voltage-clampFig. 6. MLA does not inhibit basal GABA release onto dentate gyrus granule cells. A, Rep
1 nM MLA. 50 mM Bicuculline (þBic) was applied at the end of the experiment to block all I
MLA. C, Frequency of IPSCs in control and in 1 nM MLA. D, Representative whole-cell G
transfection, in the absence (left) or presence of 1 nM MLA (right). MLA was pre-applied fo
GABA-currents by 1 nM MLA. n ¼ 5e6; NS e not signiﬁcant.recordings of spontaneous inhibitory postsynaptic currents (IPSCs)
were performed in dentate gyrus granule cells (DGGCs), which
express a2, b2 and g2 subunits, amongst others.
DGGCs receive inhibitory inputs from local interneurons origi-
natingwithin thedentategyrus andwe initially studiedwhetherany
endogenous nAChRs affected GABA release. Although the DGGC
holding current was slightly reduced by 1 nMMLA, the frequency of
IPSCs remained unaltered (Control: 4.12 ± 0.9 Hz; þMLA:
3.75 ± 1.2 Hz; n ¼ 5; P > 0.05 two-tailed t-test; Fig. 6A, C). The IPSC
amplitudes were also unaffected by 1 nM MLA (Control: median
IPSC 30.82 pA, n ¼ 5252; þMLA: 30.21 pA, n ¼ 6098; P > 0.05;
Fig. 6AeB). Furthermore, in HEK-293 cells, 1 nM MLA did not affect
the amplitude of GABA-activated currents of a2b2g2 receptors
(Fig. 6DeE). These results indicated that the release of GABA onto
DGGCs from interneurons is not subject to basal control by a7
subunit-containing nAChRs and that MLA does not affect the
amplitude of IPSCs. Nevertheless, as a precaution, we included 1 nM
MLA in all recording solutions to obviate any a7 nAChR-mediated
effects that may have confounded the interpretation of our results.
Then we examined whether a-Bgtx affected GABA release, but
the frequency of IPSCs were unaltered by 5 mM a-Bgtx, (Control:resentative IPSC recording from a dentate gyrus granule cell in control aCSF and after
PSCs B, Cumulative probability distributions of IPSC amplitudes in control and in 1 nM
ABA-activated currents from HEK-293 cells expressing a2b2g2 receptors, 48 h after
r 1 min before co-application with GABA. E, Bargraph showing the lack of inhibition of
S. Hannan et al. / Neuropharmacology 93 (2015) 28e40362.57 ± 0.51 Hz, n ¼ 8; P > 0.05; þa-Bgtx: 2.17 ± 0.34 Hz, n ¼ 8,
Fig. 7A, C). This also discounted the prospect of other non-a7-
containing nAChRs affecting basal release of GABA from in-
terneurons onto DGGCs. However, the median IPSC amplitude was
reduced by a-Bgtx (23.19 pA; n ¼ 6359) compared to control
(26.55 pA; n ¼ 6420) suggesting that a-Bgtx inhibits endogenous
synaptic GABAARs in acute hippocampal slices (Fig. 7B).
The distribution of peak IPSC amplitudes in control and in the
presence of a-Bgtx was best described by the sum of four Gaussian
components. The mean values for these components in control
(Fig. 7D) were reduced by a-Bgtx (Fig. 7E). The leftward shifts of the
ﬁrst (from 17.12 pA to 13.66 pA) and second peaks
(from 27.69 pA to 19.01 pA) were signiﬁcant (<0.001 and
P < 0.01, respectively). Although there was a tendency for the two
higher means to also be reduced in a-Bgtx, no statistical signiﬁ-
cance was observed. This may possibly be because they represent
currents mediated by receptors predominantly composed non a2-
containing receptors that are less sensitive to a-Bgtx.
As a-Bgtx could inhibit postsynaptic GABAARs, it was plausible
that extrasynaptic GABAARs, which contain bea interfaces, might
also be blocked by a-Bgtx thus affecting tonic inhibition. However,
there was no change in RMS noise in the presence (3.39 ± 0.59 pA,
n ¼ 6) or absence of 5 mM a-Bgtx (3.55 ± 0.59 pA, n ¼ 6; P > 0.05,
two-tailed unpaired t-test; Fig. 8AeB). Application of bicucullineFig. 7. a-Bgtx inhibits phasic inhibition in hippocampal neurons. A, Spontaneous IPSCs
control aCSF and in the presence of 5 mM a-Bgtx (þa-Bgtx). Bicuculline (þBic, 50 mM) was app
present throughout this experiment. B, Averaged IPSCs of 1500 events showing a reduction
Frequency of IPSCs in control aCSF (black) or in the presence of a-Bgtx (gray). NS e not signi
(E). The parameters for each of the four Gaussians used to obtain optimal ﬁts to the data a(50 mM) reduced RMS noise signiﬁcantly (2.74 ± 0.34 pA, n ¼ 6;
P < 0.05, Fig. 8AeB) compared to a-Bgtx, indicating the size of the
tonic GABAergic current. Similarly, when DGGC holding currents
were compared, no change was observed following the application
of a-Bgtx (1.27 ± 1.21 pA, n¼ 7; Fig. 8A, C) although the cells had an
average tonic current of 9.31 ± 2.52 pA (n¼ 7) revealed by applying
50 mM bicuculline. This tonic current was signiﬁcantly higher than
change in holding current observed after the application of a-Bgtx
(P < 0.05, Fig. 8C).
To probe the extrasynaptic receptors further, we studied the
interaction of recombinant a4b2d receptors by a-Bgtx in HEK-293
cells, chosen because DGGCs predominantly express a4 and d sub-
units, which, most likely, mediate the majority of the tonic inhibi-
tion in the DG (Pirker et al., 2000; Stell et al., 2003; Sun et al., 2004).
To ensure the HEK-293 cells expressed d subunit-containing
receptors, the superagonist ability of THIP (300 mM) at abd re-
ceptors was conﬁrmed by comparison with responses induced by
maximal GABA concentrations (1 mM; Fig. 9A) (Brown et al., 2002;
Mortensen et al., 2010). Surprisingly, a-Bgtx potentiated submaxi-
mal GABA responses (1 mM; Fig. 9B) at a4b2d receptors at 5 mM
(46 ± 5%, n ¼ 3; p < 0.001; Fig. 9CeD) and 20 mM (40 ± 6%, n ¼ 3;
p < 0.001, One-way ANOVA; Fig. 9C, E). This potentiation was
observedwhen a-Bgtx was pre-applied to, but not when co-applied
with, GABA (Fig. 9F).recorded from adult mouse dentate gyrus granule cells in acute slices (P115e125) in
lied to conﬁrm the GABAergic nature of the postsynaptic currents. Note: 1 nMMLAwas
of amplitudes from (A) in control aCSF (black) or in the presence of a-Bgtx (gray). C,
ﬁcant. D, E IPSC amplitude histograms in control aCSF (D) and in the presence of a-Bgtx
re shown below. Data in (D) and (E) contain approximately 13000 events.
Fig. 8. a-Bgtx and tonic inhibition. A, Representative IPSCs recorded from dentate gyrus granule cells from acute adult hippocampal slices (P115e125) in control aCSF followed by
5 mM a-Bgtx and 1 nM MLA (þa-Bgtx). Bicuculline (50 mM) was added after a-Bgtx to block GABAARs and assess the extent of the GABA tonic current. B, Root mean square (RMS)
noise from DGGCs in control, and after a-Bgtx and then in bicuculline. RMS noise was only signiﬁcantly reduced in bicuculline (n ¼ 6, P < 0.05, unpaired two-tailed t-test). C, Net
changes in tonic current after application of a-Bgtx or bicuculline.
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(56± 3.7 pA, n¼ 3) and 20 mM a-Bgtx (75± 13 pA, n¼ 3; Fig. 9GeH)
when a-Bgtx was pre-applied which may reﬂect a degree of
spontaneous activity for a4b2d receptors in the absence of GABA
similar to that described for a4b3d receptors (Tang et al., 2010). Pre-
application of a-Bgtx may therefore shut spontaneously open
a4b2d receptors. Interestingly though, GABA-activated currents
were now potentiated by a-Bgtx, when we would have expected a
block similar to that observed with abg receptors. Thus a-Bgtx in-
hibits spontaneously opening a4 and d subunit-containing re-
ceptors but with GABA binding, a-Bgtx is transformed into a
potentiator. The mechanism for this is unclear, but may arise by the
blocked spontaneously-active channels exhibiting a higher afﬁnity
for GABA resulting in a potentiated agonist-activated response.
Alternatively, once spontaneity is reduced and GABA is bound, a-
Bgtx could bind to another site on the abd from which it acts as a
positive allosteric modulator. The corollary of this is that a-Bgtx
block of spontaneous channels is not equivalent to a-Bgtx block of
GABA-activated abg receptors.
Given the reduction in the leak current in HEK-293 cells, why do
we not see any effect of a-Bgtx on tonic inhibition in neurons? The
reduction in the leak current by 5 mm a-Bgtx for HEK-293 cells
expressing a4b2d is over 40-fold greater compared to any reduction
by a-Bgtx of the leak in DGGCs. The reasons for this difference may
reﬂect the extent of over-expression of recombinant receptors and
differential post-translational processing in cell lines (Tang et al.,
2010) that may cause signiﬁcant levels of spontaneous activity
that is not replicated under more physiological conditions. It could
also reﬂect a role for the d subunit in limiting the binding of a-Bgtx
to abd receptors in a neuronal setting. If tonic inhibition is mostly
due to basal GABA-activated current rather from spontaneously
opening receptors in the DGGC, on the basis of the recombinant
receptor data, we would expect a-Bgtx to slightly potentiate rather
than inhibit tonic current. Overall, these results suggest that a-Bgtxdoes not inhibit extrasynaptic GABAA receptors, but will inhibit
synaptic axb2g2 containing receptors that are most likely popu-
lated by the a2b2g2 isoform.
4. Discussion
a-Bgtx is a widely recognised tool for studying the trafﬁcking,
expression and inhibition of nAChRs in the nervous system
(Changeux et al., 1970; Harel et al., 2001). Its use for imaging has
been extended to other receptors, e.g., GABAARs, by enabling a-Bgtx
binding. However, there is little detailed information onwhether a-
Bgtx could inhibit GABAARs, though we do know it can affect the
function of b3 subunit homomers (McCann et al., 2006). Here, we
provide the ﬁrst report that a-Bgtx can bind to and inhibit re-
combinant and native neuronal GABAARs in a mixed inhibitory
manner.
Our ﬁndings serve as a cautionary note. Firstly, using a-Bgtx to
study nAChR function in the nervous system will not be speciﬁc
unless attention is paid to the concentrations used. Secondly, the
use of a-Bgtx as a tool to study receptor trafﬁcking gained popu-
larity because a 13-amino acid mimotope (WRYYESSLEPYPD; Harel
et al., 2001) forms a high afﬁnity a-Bgtx binding site (BBS) and this
can be introduced into receptors relatively easily, enabling a-Bgtx
binding. The BBS has been engineered into: GluA2 AMPA receptor
(Sekine-Aizawa and Huganir, 2004), GABAAR a2 (Brady et al., 2014),
b3 (Bogdanov et al., 2006; Saliba et al., 2007), g2 (Joshi et al., 2013),
and d (Joshi et al., 2013) subunits: GABAB R1a (Hannan et al., 2011),
R1b (Hannan et al., 2012) and R2 subunits (Hannan et al., 2011);
mGluR2 (Hannan et al., 2012); Kv4.2 channels (Moise et al., 2010),
and Ca2þ channel a2d-2 subunits (Tran-Van-Minh and Dolphin,
2010). This approach has greatly improved our understanding of
receptor trafﬁcking and expression. However, for imaging studies
with ﬂuorophore-linked a-Bgtx, its ability to bind to native
GABAARs could complicate the interpretation of results.
Fig. 9. a-Bgtx does not inhibit GABA-activated a4b2d currents. A, Representative whole-cell GABA-activated currents from HEK-293 cells expressing a4b2d receptors in response
to sub-maximal (1 mM) and maximal GABA concentrations (1 mM) in comparison to 300 mM THIP. B, GABA concentration response curve for a4b2d receptors expressed in HEK-293
cells. Experiments were performed 48 h after transfection. pEC50: 6.04 ± 0.12 (n ¼ 5) and EC50 ¼ 0.91 mM. C, Representative whole-cell GABA-activated currents in response to
submaximal (1 mM) concentrations of GABA in the absence (left-panels) and presence of 5 and 20 mM a-Bgtx (pre-applied for 30s) in HEK-293 cells. D, Potentiation of 1 mM GABA-
activated current by 5 mM a-Bgtx compared to control (Con). E, Potentiation of 1 mM GABA-activated current by 20 mM a-Bgtx compared to control (Con). F, Representative whole-
cell GABA-activated currents in response to a maximal GABA concentration in the absence (left panel) and presence (right panel) of 5 mM a-BgTx with (bottom panel) or without
(top panel) a 30s pre-application of a-BgTx. G, Representative GABA-activated maximal currents before, during, and after application of 5 mM a-Bgtx. Note the change in leak current
during a-Bgtx). H, Changes to leak current in control (Con), þ5 mM and þ20 mM a-Bgtx *P < 0.05, **P < 0.01, ***P < 0.001, n ¼ 3e7, unpaired two-tailed t-test and One-way ANOVA.
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associated with a-Bgtx binding to principally nAChRs. For example,
AMPAR (Sekine-Aizawa and Huganir, 2004), GABAAR (Brady et al.,
2014) and GABABR (Hannan et al., 2011, 2012) trafﬁcking studies
have used d-Tc to prevent binding of a-Bgtx to nAChRs. From our
and other studies, it is clear that high doses of d-Tc can prevent a-
Bgtx binding to GABAARs, but also cause direct inhibition of GABA-
activated currents. Another strategy to avoid complications would
be to limit the over-expression of GABAARs by using a controlled
transfection of only speciﬁc subunits (Joshi et al., 2013). In this
regard, over-expression of b3 subunits could result in the formation
of homomers with b3eb3 interfaces, which bind to a-Bgtx without
the need for an engineered BBS.In addition, low concentrations of ﬂuorophore-conjugated a-
Bgtx can also be used to avoid labelling of GABAARs as the afﬁnity
of a-Bgtx for endogenous GABAARs is lower compared to that for
the BBS. Under our experimental conditions, we do not observe
any binding of ﬂuorescent a-Bgtx (400 nM) during live cell
confocal microscopy to E18 rat hippocampal cultured neurons.
These cultures express very low levels of a7 nAChRs and robust
staining with a-Bgtx can only be observed at this concentration
(400 nM) when the neurons are transfected with membrane
expressing BBS-tagged receptors. Similarly, the over-expression of
recombinant receptors in heterologous expression systems (HEK-
293 cells) allows the detection of a-Bgtx ﬂuorescence at low
concentrations.
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share many common structural features, they exhibit relatively
distinct pharmacological proﬁles. However, there are circum-
stances where some ligands can affect more than receptor type,
notably GABAAR b3 homomers binding of a-Bgtx (McCann et al.,
2006). In the present study, we extend this observation to a-Bgtx
inhibiting physiologically-important GABAAR heteromers. In addi-
tion to a7 homomers, a-Bgtx also inhibits abgd or abdε heteromeric
nAChRs. This suggests that the a-Bgtx binding site on heteromeric
GABAARs may share a similar architecture to the binding site found
on heteromeric nAChRs whereas the b3 a-Bgtx binding could be
similar to homomeric nAChRs. The b3-homomeric receptors are a
pharmacologically distinct population of GABAARs that do not
respond to GABA, but are sensitive to potentiation by bicuculline
(Wooltorton et al., 1997). Therefore, the a-Bgtx binding site on
these homomers is likely to be different from binding site on abg
heteromers. For muscle-type nAChRs, a-Bgtx binding occurs at the
interface between a-g and a-d subunits. From our study, the two
bea interfaces of abg GABAARs (which are comparable to the a-g,
a-d nAChR interfaces (Smart and Paoletti, 2012)), could therefore
contain a similar a-Bgtx binding site. This deduction is based upon
the abolition of ﬂuorophore-linked a-Bgtx binding to GABAARs by
competitive GABA receptor antagonists. This is in accord with a-
Bgtx binding at the GABA-binding bea interface, enabling a-Bgtx to
be used as a tool to study GABAAR function. However, for a4b2d
receptors, GABA responses were not inhibited by a-Bgtx. This was
surprising since these receptors will retain the bea interfaces, so
wemust presume the ﬁfth subunit (d) does have some inﬂuence on
whether a-Bgtx will bind and cause inhibition.
Proﬁling a-Bgtx binding (by ﬂuorescence) and inhibition (by
electrophysiology) at low concentrations demonstrated that the
highest levels of both were achieved with a2b2g2 receptors. This
preference for a2b2g2 is likely to reﬂect different binding afﬁnities
of a-Bgtx for various b2-ax interfaces, presumably because of
divergent amino acid sequences between the different a subunits
on the complementary () (as opposed to the principal side (þ))
side of the bea subunit interface (Smart and Paoletti, 2012). From
the ﬂuorescent a-Bgtx binding proﬁles of axb1g2 receptors, we
would expect the a-Bgtx inhibitory proﬁles to be similar, with
a2b1g2 being inhibited most and a5b1g2 least, by a-Bgtx.
The receptor subtype selectivity of a-Bgtx is useful for studying
native GABAAR function in acute hippocampal slices, without any
dependence upon nAChRs. Application of MLA revealed that pre-
synaptic a7-containing nAChRs are not regulating the basal release
of GABA onto adult DGGCs. However, previous reports suggest that
nAChR-activation can cause increased GABA release (Radcliffe
et al., 1999), though, MLA had no effect on basal GABA release in
mouse CA1 pyramidal neurons (Proctor et al., 2011) and layer V
prefrontal cortex (Aracri et al., 2010). In addition, a-Bgtx neither
affected the average tonic current nor the RMS noise suggesting
that other subtypes of nAChRs do not control basal GABA release
in the dentate. This further suggested that a-Bgtx, at concentra-
tions speciﬁc for inhibiting a2 subunit-containing receptors, has
little if any effect on a4 or a5 subunit-containing extrasynaptic
receptors.
The inhibitory effect of a-Bgtx on IPSC amplitudes in adult slices
was rapid in onset. The reduced IPSC amplitudes were more pro-
nounced for smaller compared to larger events, and given the
selectivity of a-Bgtx, implies that a2b1/2g2 receptors contribute
largely to these sub-populations of events. Of course, a small pro-
portion of IPSCs may be inhibited by the binding of a-Bgtx to b3
subunit-containing receptors. Nevertheless, the binding of a-Bgtx
to heteromeric GABAARs together with the inhibition of GABA-
activated currents in HEK-293 cells, primary hippocampal neu-
rons and in slices, clearly indicates that a-Bgtx can act as anantagonist at native GABAARs to block synaptic inhibition, pre-
sumably by binding at the GABAA receptor bea interface.Author contribution
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